Roche Submits sNDA For New Chemotherapy Regimen In Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Application is for Xelox (Xeloda plus oxaliplatin) with or without Genentech’s Avastin.
You may also be interested in...
Genentech Avastin Approved For Colorectal Cancer With Five-Month Survival Benefit
The angiogenesis inhibitor gets full FDA approval Feb. 26. Genentech said it will begin shipping the biologic within three days.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.